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One Sentence Summary: Corticosterone is excluded from adipose tissue by the trans-24 
membrane transporter ABCC1 and is as effective as cortisol for ACTH suppression, but lacks 25 
metabolic adverse effects. 26 
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Abstract 27 
The aim of treatment in congenital adrenal hyperplasia is to suppress excess adrenal androgens 28 
while achieving physiological glucocorticoid replacement. However, current glucocorticoid 29 
replacement regimes are inadequate, because doses sufficient to suppress excess androgens 30 
almost invariably induce adverse metabolic effects. Although both cortisol and corticosterone are 31 
glucocorticoids that circulate in human plasma, any physiological role for corticosterone has 32 
been neglected. In the brain, the ATP-binding cassette transporter ABCB1 exports cortisol but 33 
not corticosterone. Conversely, ABCC1 exports corticosterone but not cortisol. We show that 34 
ABCC1 but not ABCB1 is expressed in human adipose, and that ABCC1 inhibition increases 35 
intracellular corticosterone but not cortisol and induces glucocorticoid-responsive gene 36 
transcription, in human adipocytes. Both C57Bl/6 mice treated with the ABCC1 inhibitor 37 
probenecid and FVB mice with deletion of Abcc1 accumulated more corticosterone than cortisol 38 
in adipose after adrenalectomy and corticosteroid infusion. This accumulation was sufficient to 39 
increase glucocorticoid-responsive adipose transcript expression. In human adipose tissue, tissue 40 
corticosterone concentrations were consistently low, and ABCC1 mRNA was upregulated in 41 
obesity. To test the hypothesis that corticosterone effectively suppresses ACTH without the 42 
metabolic adverse effects of cortisol, we infused cortisol or corticosterone in patients with 43 
Addison’s disease. ACTH suppression was similar, but subcutaneous adipose transcripts of 44 
glucocorticoid-responsive genes was higher after cortisol than corticosterone. These data indicate 45 
that corticosterone may be a metabolically favorable alternative to cortisol for glucocorticoid 46 
replacement therapy when ACTH suppression is desirable, as in congenital adrenal hyperplasia, 47 
and justify development of a pharmaceutical preparation.   48 
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Introduction 49 
Congenital adrenal hyperplasia (CAH) is characterized by impaired adrenal steroidogenesis, 50 
with glucocorticoid deficiency resulting in reduced suppression of adrenocorticotrophic 51 
hormone (ACTH), and hence ACTH-dependent adrenal androgen excess. Current treatment 52 
guidelines recommend cortisol (hydrocortisone) as the treatment of choice, but recent studies 53 
have found that the doses required to suppress adrenal androgen production are usually 54 
associated with adverse effects (1, 2), notably in adipose tissue where chronic glucocorticoid 55 
excess promotes obesity and associated metabolic dysfunction (3). The ideal treatment would 56 
have higher potency in suppressing ACTH and lower potency as a glucocorticoid acting in 57 
peripheral tissues. Here, we provide a rationale and proof of concept for using corticosterone 58 
therapy as an alternative to hydrocortisone (cortisol). 59 
A neglected characteristic of the hypothalamus-pituitary-adrenal (HPA) axis is that 60 
many species produce two glucocorticoids, cortisol and corticosterone, unlike rats and mice 61 
that lack 17-hydroxylase (CYP17) in their adrenals and therefore secrete only corticosterone. 62 
Although results of human glucocorticoid receptor binding studies are inconsistent (4, 5), 63 
both glucocorticoids appear to have similar affinities for mineralocorticoid receptors (6) and 64 
are subject to similar metabolism (7). However, there is emerging evidence for tissue-specific 65 
responses to cortisol and corticosterone, mediated by differential susceptibility to 66 
transmembrane transport by ATP-binding cassette (ABC) transporters (8-12). In rodents, 67 
ABCB1 (also known as multidrug resistance protein 1, MDR1, or p-glycoprotein) exports 68 
cortisol but not corticosterone across the blood-brain barrier (10, 12). Disproportionately high 69 
corticosterone concentrations in cerebrospinal fluid and brain tissue suggest that the same 70 
mechanism operates in humans (10, 13). Another transporter, ABCC1 (or multidrug 71 
resistance-related protein 1, MRP1), exports corticosterone but not cortisol in vitro (11). We 72 
show expression of ABCC1 but not ABCB1 in human adipose tissue, report in vitro and in 73 
vivo data supporting the hypothesis that adipose tissue excludes corticosterone and is 74 
preferentially sensitive to cortisol, and provide proof of concept that corticosterone may be a 75 
useful therapy especially when suppression of ACTH is desirable, as in CAH.  76 
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Results  77 
ABCC1 but not ABCB1 is expressed in human adipose 78 
In a transcriptomic analysis of ABC transporters in healthy men, ABCC1 but not ABCB1 was 79 
highly expressed in subcutaneous adipose tissue (Figure 1A and figure S1). This pattern was 80 
confirmed by conventional reverse transcriptase polymerase chain reaction amplification in 81 
human adipose tissue and in differentiated SGBS human adipocytes (Figure 1B) (14), in which 82 
we also confirmed that ABCC1 protein and mRNA are regulated in parallel, for example when 83 
we induced ABCC1 by incubation with lipopolysaccharide (figure S2). However, in murine 84 
adipose tissue, both ABCB1 and ABCC1 were expressed (Figure 1C). Publicly available datasets 85 
do not provide sufficient data to test for patterns of ABCB1 and ABCC1 expression in multiple 86 
species, but we also found selective adipose expression of ABCC1 but not ABCB1 in horse, 87 
another species in which both cortisol and corticosterone are in the circulation (Figure 1D).  88 
ABCC1 preferentially exports corticosterone and confers sensitivity to cortisol in human 89 
adipocytes in vitro 90 
After incubation of SGBS adipocytes with cortisol or corticosterone for 24 hours, removal of 91 
extracellular steroid resulted in lower intracellular concentrations of corticosterone compared to 92 
those of cortisol over the subsequent 24 hours (Figure 2A), suggesting active preferential export 93 
of corticosterone. This was confirmed and attributed to ABCC1 using the inhibitors MK571 (15) 94 
and probenecid (11). MK571 concentrations (10 M) sufficient to inhibit ABCC1-dependent 95 
export of calcein by ~40% in SGBS cells (figure S3A) (16) increased accumulation of 96 
intracellular deuterated corticosterone assessed qualitatively using coherent anti-Stokes Raman 97 
scattering (CARS) microscopy (Figure 2B). Similarly, both MK571 and probenecid increased 98 
intracellular tritiated corticosterone much more so than tritiated cortisol (Figure 2C). Effects of 99 
MK571 and probenecid on corticosterone retention were time-dependent (figure S3B) and dose-100 
dependent (figure S3C,D). 101 
To test the consequences of ABCC1-mediated steroid transport for glucocorticoid receptor (GR) 102 
activation, we used A549 human epithelial cells (which express ABCC1 and GR) transfected 103 
with a glucocorticoid-responsive MMTV-luciferase reporter (17). The response was greater to 104 
cortisol than corticosterone without inhibition of ABCC1, and MK571 potentiated luciferase 105 
induction by corticosterone but not cortisol (figure S4A). In differentiated SGBS adipocytes, we 106 
tested a panel of known GR-responsive gene transcripts to determine a suitable candidate for 107 
assessing acute cortisol versus corticosterone sensitivity (Figure 2D). Of these, only PER1 was 108 
induced acutely (2 hours) by glucocorticoids, consistent with its rapid response (18) and high 109 
sensitivity (19) in other systems. We showed greater sensitivity to cortisol than corticosterone for 110 
induction of PER1 transcription (Figure 2D). MK571 directly increased the amount of this 111 
transcript (figure S4B), so probenecid was used alone as an ABCC1 inhibitor, reversing the 112 
differential sensitivity to cortisol over corticosterone (Figure 2D). Similar results were obtained 113 
after 24 hour incubations (figure S4C). Finally, to confirm whether adipocytes are functionally 114 
more sensitive to cortisol than corticosterone, SGBS preadipocytes were differentiated in the 115 
presence of glucocorticoid; cortisol but not corticosterone induced marked triglyceride 116 
accumulation over 21 days (Figure 2E).  117 
 118 
Genetic disruption or pharmacological inhibition of Abcc1 in mice results in preferential 119 
accumulation of corticosterone in adipose tissue 120 
Male control mice (Abcc1+/+) and mice deficient in Abcc1 (Abcc1-/-) on a FVB genetic 121 
background were adrenalectomized and infused with corticosterone and cortisol by subcutaneous 122 
osmotic minipump for 7 days, followed by measurement of steroids in plasma and tissue by 123 
liquid chromatography tandem mass spectrometry (LC-MS/MS). Plasma analysis (Figure 3A) 124 
indicated impaired clearance of glucocorticoids in Abcc1-/- mice, with elevated steady state 125 
concentrations of corticosterone and a trend to elevated cortisol compared with control mice, but 126 
there was no difference in the circulating corticosterone:cortisol ratio. In the brain (Figure 3B), 127 
corticosterone concentrations were higher in Abcc1-/- mice than controls, consistent with 128 
increased plasma concentrations, and cortisol was low in both groups, consistent with exclusion 129 
of cortisol by ABCB1 (10). However, there was no effect of ABCC1 deficiency on brain 130 
corticosterone:cortisol ratio. In contrast, in subcutaneous adipose tissue (Figure 3C), Abcc1 131 
deficiency resulted in an elevated corticosterone:cortisol ratio, with a marked increase in 132 
corticosterone but not cortisol concentrations. 133 
To assess if pharmacological inhibition of ABCC1 mimicked the effects of genetic deletion on 134 
adipose glucocorticoid concentrations, we treated mice with probenecid. Male C57Bl/6 mice 135 
underwent the same adrenalectomy and steroid infusion protocol as Abcc1+/+ and Abcc1-/- mice, 136 
and were treated with probenecid (150 mg/kg/day) or vehicle (saline). Probenecid did not alter 137 
corticosterone or cortisol concentrations in the plasma (Figure 3D) or in the brain (Figure 3E); 138 
however, consistent with the results from Abcc1-/- mice, probenecid increased corticosterone but 139 
not cortisol concentrations in subcutaneous adipose tissue (Figure 3F).  140 
To test the metabolic consequences of the increase in intra-adipose corticosterone concentrations 141 
with ABCC1 inhibition, we repeated the experiment with probenecid, adding an additional 142 
control group with no glucocorticoid infusion, and assessed adipose tissue for glucocorticoid-143 
responsive gene transcripts (Figure 4). Plasma corticosterone and cortisol concentrations were 144 
unaffected by probenecid in corticosteroid-infused groups, as before (Figure 4A), and below the 145 
lower limit of detection (0.5 ng/ml) in vehicle-treated adrenalectomized animals. Corticosteroid 146 
infusion reduced weight gain during the 7-day treatment (Figure 4B) and induced adipose 147 
expression of Per1, Atgl, Hsl, and Lpl (Figure 4C); the effects on body weight and adipose Per1, 148 
Atgl, and Lpl were potentiated by probenecid (Figure 4B,C).  149 
Corticosterone concentrations are low in human adipose, and not increased in obesity  150 
To compare endogenous cortisol and corticosterone concentrations in adipose tissue, and to test 151 
whether downregulation of ABCC1 might enhance corticosterone action in adipose tissue in 152 
obesity, we collected subcutaneous and visceral adipose biopsies during elective abdominal 153 
surgical procedures from 6 lean and 6 obese patients, with characteristics shown in table S1. 154 
ABCC1 mRNA transcripts were increased in obese subjects in both subcutaneous and visceral 155 
adipose (Figure 5A). Adipose tissue cortisol was readily measured in both adipose depots, as 156 
previously described (20), and not different between lean and obese subjects (Figure 5B). 157 
Corticosterone concentrations in lean and obese subjects were below or near the limit of 158 
detection by LC/MS-MS in both visceral and subcutaneous adipose tissue (Figure 5B).  159 
Human adipose is less sensitive to corticosterone than cortisol 160 
Having established that selective expression of ABCC1 protects human adipose tissue from 161 
corticosterone, we then tested whether corticosterone is less potent than cortisol at inducing 162 
metabolic effects in adipose. This was achieved using doses of cortisol and corticosterone 163 
equipotent for ACTH suppression. We performed a randomized single-blind crossover study in 164 
patients with Addison’s disease using sequentially increasing steady state infusions of deuterated 165 
glucocorticoids, D8-corticosterone and D4-cortisol, which can be distinguished from residual 166 
endogenous glucocorticoids by mass spectrometry (21). Characteristics of study participants are 167 
summarized in table S2. Circulating concentrations of cortisol (sum of cortisol, D4-cortisol, and 168 
its active metabolite D3-cortisol) and corticosterone (D8-corticosterone alone; endogenous 169 
corticosterone was undetectable) indicated that serially increasing steady state concentrations 170 
were achieved as intended (Figure 6A). Total steady state concentrations tended to be higher for 171 
cortisol than corticosterone, although the differences were not statistically significant and there 172 
were no differences in free cortisol and corticosterone measured after equilibrium dialysis (in 173 
samples pooled between 260 and 330 min of infusion, free cortisol = 38.7 ± 8.2 nM and free 174 
corticosterone = 37.2 ± 4.7 nM). Neither ACTH concentrations at baseline nor their suppression 175 
during glucocorticoid infusion were different between cortisol and corticosterone (Figure 6B,C; 176 
Table 1). Amongst biochemical markers of glucocorticoid action – glucose, insulin, glycerol, and 177 
free fatty acids – only free fatty acids rose during steroid infusion (Table 1), perhaps because the 178 
infusions were short and the glucocorticoid concentrations achieved were within the 179 
physiological range (22). Insulin concentrations fell, paradoxically, during steroid infusions. 180 
None of these plasma biochemical markers differed between D8-corticosterone and D4-cortisol 181 
infusion (Table 1). However, in subcutaneous adipose biopsies obtained at the end of infusions, 182 
the acutely responsive glucocorticoid-responsive transcript PER1 was substantially higher and 183 
LPL also modestly higher after D4-cortisol than D8-corticosterone infusion (Figure 6D).  184 
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Discussion  185 
Our findings shed light on tissue-specific responsiveness to cortisol and the often-neglected 186 
‘second’ glucocorticoid corticosterone, mediated by local expression of steroid-selective ABC 187 
transporters. In combination with tissue-specific expression of either mineralocorticoid or 188 
glucocorticoid receptors and tissue-specific intracellular metabolism of corticosteroids, the 189 
availability of alternate endogenous glucocorticoids that are differentially transported out of 190 
target cells provides a mechanism for subtle control of the otherwise highly conserved pathway 191 
of glucocorticoid action. Moreover, as summarized in the schematic in Figure 7, our data show 192 
how this insight can be exploited to develop corticosterone as a potentially safer alternative to 193 
cortisol for glucocorticoid replacement therapy when ACTH suppression is desirable. 194 
For in vitro studies, we used SGBS adipocytes, an established model of human 195 
adipocytes (14), to show that in the absence of ABCB1, endogenous ABCC1 expression is 196 
sufficient to reduce intracellular corticosterone but not cortisol concentrations. An equilibrium in 197 
intracellular cortisol and corticosterone concentrations was reached after approximately 4 hours 198 
in adipocytes. Our CARS microscopy data suggest that glucocorticoids co-localize with lipid 199 
droplets within adipocytes, potentially resulting in their intracellular retention and explaining the 200 
slow turnover of cortisol in adipose tissue in vivo (20). The magnitude of the effect of ABCC1 201 
on steroid export appears to be substantial, with a 3-4 fold increase in intracellular corticosterone 202 
when ABCC1 is inhibited in SGBS cells, and a 2-fold increase in adipose corticosterone in vivo 203 
in mice. In a physiological context, if the plasma glucocorticoid pool is comprised of 90-95% 204 
cortisol and 5-10% corticosterone, as reported in previous studies (10, 13, 23-32) (table S3), the 205 
total (cortisol plus corticosterone) intra-adipose glucocorticoid pool may be reduced by as much 206 
as ~7% as a result of ABCC1 activity. In a pathological context, we hypothesized that reduction 207 
of adipose ABCC1 in obesity might contribute to metabolic dysregulation through increased 208 
intra-adipose corticosterone. However, ABCC1 expression was increased in obesity, suggesting a 209 
potential protective mechanism to limit adipose exposure to glucocorticoids, which is considered 210 
to be beneficial in obesity (3). Indeed, adipose glucocorticoid concentrations were consistent 211 
with ABCC1 acting as constitutive barrier to maintain very low corticosterone concentrations in 212 
human adipose tissue, even in obese individuals. In a pharmacological context, such as if 213 
corticosterone were used as glucocorticoid replacement therapy, the consequences of ABCC1 214 
activity for the intra-adipose glucocorticoid pool could be much greater. We tested this in vivo in 215 
mice and humans. 216 
Our findings in vivo support our cell-based work, with both genetic deletion and 217 
pharmacological inhibition of ABCC1 resulting in preferential accumulation of corticosterone 218 
over cortisol in the adipose tissue. Because 17α-hydroxylase, which is necessary to produce 219 
cortisol, is not expressed in mouse adrenals, we studied this in adrenalectomized mice infused 220 
with equal concentrations of both glucocorticoids. Plasma steroid concentrations achieved during 221 
infusion were similar within strains, but slightly higher in C57Bl6 than FVB mice, potentially 222 
reflecting strain-specific differences in glucocorticoid clearance. Abcc1-/- mice, but not mice 223 
treated with probenecid, showed higher steady-state plasma concentrations of cortisol and 224 
corticosterone compared to wild type controls, implicating ABCC1 in total glucocorticoid 225 
clearance; this effect, however, appears to require total loss of ABCC1, as it was not observed 226 
with a competitive inhibitor, probenecid. Of note, the only spontaneous phenotype reported in 227 
Abcc1-/- mice is a reduced susceptibility to inflammation (33), which may be mediated by 228 
systemic or intracellular corticosterone excess, but this has not been studied. Using probenecid, 229 
we showed that the increase in intra-adipose corticosterone concentrations with ABCC1 230 
inhibition is sufficient to potentiate the induction of key lipolytic genes (Atgl and Hsl) and 231 
prevent weight gain.  232 
To investigate the physiological and therapeutic implications of these findings, we 233 
performed a study in patients with Addison’s disease, who lack endogenous glucocorticoids. We 234 
selected patients with Addison’s disease rather than with CAH to avoid confounding effects of 235 
high androgen concentrations in the adipose tissue. Corticosterone is only available as an 236 
experimental tool for infusion and not as a licensed pharmaceutical, therefore only short-term 237 
manipulation was possible. At similar concentrations of free cortisol and corticosterone, we 238 
found equipotent suppression of ACTH, but substantially greater gene transcript induction in 239 
adipose tissue by cortisol. In adipose, cortisol induced greater transcript expression than 240 
corticosterone not only for PER1, which is known to be rapidly induced by glucocorticoids (18) 241 
and sensitive at low concentrations which do not alter other glucocorticoid-responsive genes 242 
(19), but also for LPL, a key enzyme involved in adipose triglyceride uptake. The lack of 243 
differences in circulating metabolic markers is likely attributable to the short duration of 244 
infusions and the glucocorticoid concentrations within the physiological range (22); previous 245 
studies have that demonstrated plasma glucose, insulin, and glycerol show responses only to 246 
several hours of ‘physiological’ glucocorticoid infusion (34, 35). It remains possible that there 247 
are intrinsic differences in transcriptional response to cortisol and corticosterone in human 248 
adipose tissue, even when the same concentrations of steroid are present, but this seems unlikely 249 
given our findings in SGBS adipocytes that cortisol is no more potent than corticosterone when 250 
ABCC1 is inhibited. Despite our confirmation that cortisol concentrations are disproportionately 251 
low in the mouse brain, and earlier observations of relatively low cortisol in human brain and 252 
cerebral spinal fluid (10, 13), we did not find that corticosterone was more effective than cortisol 253 
in suppressing ACTH. This may reflect the major feedback signal being mediated in the pituitary 254 
rather than higher centers within the brain, under non-stressed conditions. Nonetheless, the 255 
discrepancy between suppression of ACTH and induction of adipose PER1 and LPL by cortisol 256 
versus corticosterone supports our interpretation that adipose tissue is physiologically more 257 
responsive to cortisol than corticosterone, and that this can be exploited therapeutically.  258 
Synthetic glucocorticoids in common use as glucocorticoid therapy, specifically 259 
prednisolone and dexamethasone, are not transported by ABCC1 (11) and so are likely to access 260 
adipose tissue similarly to cortisol. To validate and exploit these findings, it will therefore be 261 
important to develop a suitable pharmaceutical preparation of corticosterone. With longer term 262 
therapy, corticosterone and cortisol effects can be compared in conditions requiring effective 263 
ACTH suppression such as CAH, Nelson’s syndrome, and glucocorticoid-suppressible 264 
hyperaldosteronism. Although we have focused here on adipose tissue, differential expression of 265 
ABCB1 and ABCC1 may determine tissue-specific responses to corticosterone and cortisol in 266 
other tissues as well. Adverse effects will need to be compared not only for metabolism and 267 
obesity, but also for immune suppression and osteoporosis. Nevertheless, our findings suggest 268 
that the substantial investment required to develop a corticosterone-based drug product is 269 
worthwhile.  270 
 271 
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Materials and Methods 272 
Study design 273 
To investigate the role of adipose ABCC1 regulating cortisol versus corticosterone action, we 274 
conducted studies in cells, mice, and humans, as detailed below. In vitro experiments were 275 
performed in triplicate with the number of experiments and outcomes defined in figure legends. 276 
For in vivo studies in mice, experiments were approved by the institutional ethical committee 277 
and conducted under UK Home Office license in male mice aged 10-12 weeks at the start of the 278 
experiment. Sample sizes were chosen for 80% power to detect magnitudes of difference inferred 279 
from in vitro experiments at P<0.05, with the number of mice and outcomes defined in figure 280 
legends. Mice of each genotype were randomly assigned to interventions within each 281 
experiment. The studies in humans were conducted with approval from the South East Scotland 282 
Research Ethics Committee and NHS Lothian Research and Development (13/SS/0210 for 283 
Addison’s disease study and 10/S1102/39 for surgical adipose tissue collection study), and with 284 
written informed consent of participants. The surgical adipose tissue collection study was a case-285 
control design comparing adipose tissue mRNA amounts in lean and obese participants randomly 286 
selected from those undergoing surgery. An initial exploratory study was conducted in n=6 per 287 
group and showed results contradicting the hypothesis that ABCC1 transcripts are decreased in 288 
obesity, so the study was not expanded. For the Addison’s disease study, eligible patients 289 
participated in a single-blind randomized crossover study comparing infusions of deuterated 290 
corticosterone and deuterated cortisol for effects on ACTH, adipose tissue mRNA, and 291 
circulating metabolic indices. Blinding of the clinical investigator was impractical because of the 292 
requirements for administration of different loading and infusion doses of cortisol and 293 
corticosterone, but samples were processed in the laboratory with blinded codes and only 294 
decoded for statistical analysis; patients were blinded to treatment. Sample size was calculated 295 
for 90% power to detect 20% difference in ACTH at p<0.05. Inclusion/exclusion criteria for each 296 
study are detailed below. There were no dropouts, and no outliers were excluded from any 297 
studies.  298 
Human adipose tissue microarray  299 
Affymetrix microarray data were obtained from subcutaneous adipose biopsies of 9 healthy men, 300 
aged 36.6 ± 2.1 years with body mass indices 29.2 ± 2.1 kg/m2 (36). Probes for transcripts 301 
encoding ABC transporters were selected and ranked by transcript intensity (log2 transformed).  302 
Polymerase chain reaction 303 
Human tissue biobank cDNA (Primerdesign Ltd) was used as a template for the identification of 304 
ABC transporters in human tissue of interest. Equine peri-renal adipose tissue collection from 305 
clinical cases euthanized for reasons other than endocrine disease/systemic inflammation was 306 
approved by the University of Edinburgh Veterinary ethics and research committee. Where 307 
applicable, total RNA extraction was carried out by centrifugation in Qiazol lysis reagent using 308 
an RNeasy mini kit (Qiagen), according to the manufacturer’s instructions. RNA integrity was 309 
checked on a 1% agarose gel, after which cDNA (500 ng RNA/reaction) was synthesized using a 310 
high capacity cDNA kit (Invitrogen), according to the manufacturer’s instructions. cDNA was 311 
used as a template for specific primers (Invitrogen; table S4) for RT-PCR and amplified using 312 
GoTaq DNA polymerase (Promega) as per the manufacturer’s instructions, on a Techne 313 
thermocycler (95 C for 5 min; 35 cycles of 95 C for 30 s, 60 C for 30 s, 72 C for 30 s; 72 C 314 
for 5 min). Products were subjected to gel electrophoresis on a 2% agarose gel in TAE buffer 315 
(50x stock buffer: 2 M Tris Base, 1 M glacial acetic acid, 100 mM disodium EDTA) containing 316 
GelRed (Cambridge Bioscience). Gels were imaged using a Gel-Doc system (Uvitec). Product 317 
size was confirmed against a 100 bp DNA ladder (Invitrogen).  318 
In vitro studies 319 
SGBS cell culture 320 
Human preadipocyte Simpson-Golabi-Behmel syndrome (SGBS) cells were a kind gift from 321 
Martin Wabitsch, University of Ulm, Germany (14). Cells were maintained in high-glucose 322 
DMEM-F12 (Lonza), supplemented with FBS (10% v/v), penicillin (100 IU/ml), streptomycin 323 
(100 IU/ml), biotin (γγ μM), and pantothenic acid (17 μM) at γ7°C in 5% CO2. Differentiation 324 
was induced as previously described (37). Cells were cultured in steroid-free medium for 24 325 
hours before experimentation. 326 
Primary cell culture 327 
Subcutaneous adipose tissue samples were obtained from patients undergoing elective abdominal 328 
surgery at the Royal Infirmary of Edinburgh. Upon tissue collection, adipose was digested, and 329 
the stromal vascular fraction was isolated and differentiated as previously described (38). In 330 
brief, after removal of connective tissue and blood vessels, adipose tissue was digested in 331 
collagenase type I (615 U/g tissue, 90 min, 37 °C). After overnight plating in high-glucose 332 
DMEM-F12 supplemented with FBS (10% v/v), penicillin (100 IU/ml), streptomycin (100 333 
IU/ml), biotin (γγ μM), and pantothenic acid (17 μM), cells were differentiated for γ days using 334 
the above medium without serum, but with addition of triiodothyronine (1 nM), transferrin (10 335 
µg/ml), insulin (66 nM), IBMX (500 µM), dexamethasone (1 µM), and rosiglitazone (10 µM). 336 
From day 4 onwards, cells were maintained in this differentiation medium but without IBMX, 337 
dexamethasone, or rosiglitazone.  338 
Tritiated glucocorticoid retention assays 339 
To measure uptake and retention of steroids, SGBS adipocytes were incubated in the presence of 340 
either corticosterone or cortisol (20 nM 1,2,6,7-3H4-steroid, 480 nM unlabeled steroid) for 1, 4, 341 
8, and 24 hours before being washed in PBS, lysed in cellular lysis buffer (0.5% SDS), mixed 342 
with Prosafe FC+ liquid scintillation cocktail (Meridan Biotechnologies), and read for 1 min on a 343 
ȕ-scintillation counter. A separate batch of SGBS adipocytes were incubated with steroids for 24 344 
hours as described above, then washed in PBS before fresh steroid-free medium was added to 345 
each well and the decline in intracellular 3H-steroid content measured at 1, 4, 8 and 24 hours. 346 
To assess the effect of ABCC1 inhibition, SGBS adipocytes were pre-incubated for 1 hour in the 347 
presence of the indicated concentrations of MK-571 (Cayman Chemical), probenecid 348 
(Invitrogen), or vehicle (DMSO), before being incubated for a further 24 hours in the presence of 349 
inhibitor or vehicle and either corticosterone or cortisol (20 nM 3H-steroid, 480 nM unlabeled 350 
steroid). Cells were then washed in PBS, lysed in cellular lysis buffer, mixed with liquid 351 
scintillation cocktail, and read for 5 min on a ȕ-scintillation counter. 352 
 353 
Quantification of glucocorticoid-sensitive mRNA transcripts  354 
In accordance with the time course of the clinical study, we performed an acute (2 hour) 355 
treatment in SGBS adipocytes and an extended (24 hour) treatment with either vehicle or cortisol 356 
(500 nM) to identify acutely upregulated glucocorticoid-responsive transcripts. To determine the 357 
effects of ABCC1 inhibition on glucocorticoid-induced transcripts, SGBS adipocytes were pre-358 
incubated for 1 hour in the presence of probenecid (50 μM) or vehicle (DMSO), before a further 359 
2 or 24 hours incubation in the presence of probenecid or vehicle and either corticosterone or 360 
cortisol (500 nM). Total RNA was extracted from adipocytes in Qiazol lysis reagent using a 361 
RNeasy Mini Kit according to the manufacturer’s instructions. RNA (β50 ng) was reverse 362 
transcribed with random primers using the Applied Biosystems High-Capacity cDNA Reverse 363 
Transcription kit. Real-time PCR was performed using the Roche LightCycler 480 (Roche 364 
Applied Science). Primers (Invitrogen) were designed for use with intron-spanning probes within 365 
the Roche Universal Probe Library (UPL). Primer sequences and UPL probe numbers are shown 366 
in table S5. Results were corrected for abundance of 18S, which was not affected by treatment. 367 
All samples were analyszd in triplicate and amplification curves plotted (y axis fluorescence, x 368 
axis cycle number). Triplicates were deemed acceptable if the standard deviation of the crossing 369 
point was < 0.5 cycles. A standard curve (y axis crossing point, x axis log concentration) for each 370 
gene was generated by serial dilution of cDNAs pooled from different samples, fitted with a 371 
straight line, and deemed acceptable if reaction efficiency was between 1.7 and 2.1. 372 
CARS microscopy 373 
Coherent Anti-Stokes Raman Scattering (CARS) microscopy is a non-invasive, label-free 374 
imaging technique based on Raman spectroscopy. The experimental setup has been described 375 
previously (39). Briefly, a pump and tuneable Stokes laser (PicoTrain, High-Q laser and Levante 376 
Emerald Optical Parametric Oscillator) provided a specific vibrational coherence resulting in 377 
detectable photons which, when combined with a confocal laser scanning inverted microscope 378 
(C1 Eclipse, Nikon BV), provided a spatial image. For CARS imaging, the pump and Stokes 379 
laser beams were tuned such that the frequency difference would correspond to a specific Raman 380 
vibration. 381 
SGBS adipocytes were incubated for 24 hours in glass-bottomed dishes with 382 
2,2,4,6,6,17,21,21-2H8-corticosterone (D8-corticosterone, 10 μM; Cambridge Isotopes) in the 383 
presence or absence of MK-571 (10 μM). For CARS imaging, the pump laser was tuned to 816.8 384 
nm (12243 cm-1) and Stokes laser to 1064 nm (9398.5 cm-1) to obtain a CARS signal at 663 nm 385 
(2845 cm-1) corresponding to the vibration of CH2 in lipids (39). After initial documentation of 386 
Raman spectra to identify optimal wavelength (figure S5), excitation of the Raman vibration of 387 
the C-D bond in D8-corticosterone was achieved by adjusting the pump laser to 868.4 nm 388 
(11524.5 cm-1), resulting in a CARS signal at 733 nm (2126 cm-1), which was in a region of the 389 
Raman spectrum with low background signal. Images were processed using Nikon EZ-C1 3.4 390 
software.  391 
Protein analysis 392 
Total protein extracts from cells were prepared in RIPA buffer (Santa Cruz). Samples were 393 
sonicated and centrifuged (13,000 x g, 15 min, 4 °C) before performing the BCA assay, adding 394 
6X Laemmli sample buffer (LSB), boiling, and SDS-PAGE resolution. ABCC1 (Enzo Life 395 
Sciences, ALX-801-007) and HSP90 (Santa Cruz, sc-7947) were detected on Western blots 396 
using commercial antibodies. 397 
 398 
Oil Red O staining and lipid quantification 399 
To assess potential differing effects of cortisol and corticosterone on adipocyte differentiation, 400 
SGBS adipocytes were stimulated to undergo differentiation with or without the substitution of 401 
cortisol in the differentiation cocktail (37) for corticosterone. Accumulation of lipid during 402 
adipogenesis was visualized by Oil Red O (Sigma-Aldrich). Cells were washed twice with PBS 403 
and fixed with formalin (10% v/v) for 60 min, followed by a wash with isopropanol (60% v/v). 404 
Working Oil Red O solution was added to cells for 10 min, followed by 4 washes with H2O. 405 
Cells were air-dried and dye extracted with isopropanol (100%). Absorbance of extracts were 406 
measured at 500 nm wavelength in an OPTImax microplate reader (Molecular Devices). 407 
Calcein-AM Assay 408 
Calcein–acetoxymethyl ester (AM) is a non-fluorescent, hydrophilic, cell membrane permeable 409 
molecule which is converted to fluorescent, hydrophilic calcein by intracellular esterases (16). 410 
Both calcein-AM and calcein are substrates for ABCC1, thus intracellular fluorescence is 411 
inversely proportional to ABCC1 activity. SGBS adipocytes were washed with PBS and pre-412 
incubated for 1 hour in the presence of MK-571 (10 μM) or vehicle (DMSO), before being 413 
incubated for a further 5 hours in the presence of inhibitor or vehicle and calcein-AM (1 µM; 414 
Invitrogen). Cells were washed three times in PBS, then excitation absorbance was measured at 415 
494 nm and emission absorbance was measured at 517 nm in an Infinite M1000 plate reader 416 
(Tecan). Data are expressed as percentage fluorescence of untreated control.  417 
Luciferase reporter assay 418 
Human epithelial A549 cells were grown in DMEM (Lonza), supplemented with FBS (10% v/v), 419 
penicillin (100 IU/ml), and streptomycin (100 IU/ml). Cells were seeded at 2x105/ 35 mm well. 420 
After overnight incubation, medium was replaced with Opti-MEM (Lonza), and cells were 421 
transfected using Lipofectamine 2000 (Invitrogen) with a total of 2 µg DNA comprising 1 µg 422 
pMMTV-LTR-Luc (40) and 1 µg pKCβ75 (encoding ȕ-galactosidase as internal control). After 423 
overnight incubation, medium was replaced with steroid-free medium, and cells were treated for 424 
1 hour with MK-571 (10 μM) before a 24-hour incubation with inhibitor and either 425 
corticosterone or cortisol (500 nM). Luciferase and ȕ-galactosidase activities were measured in 426 
cell lysates as described previously (41). ȕ-Galactosidase activity was assayed using a Tropix 427 
Galacto Light Plus kit (Applied Biosystems). All transfections were carried out in triplicate, and 428 
the mean ratio of luciferase/ ȕ-galactosidase activities was calculated. 429 
Animal studies 430 
Animals 431 
Male Abcc1 knockout mice (Abcc1-/-) and FVB controls (Abcc1+/+) were purchased from 432 
Taconic. Male C57Bl/J mice were purchased from Charles River. Mice were bilaterally 433 
adrenalectomized under fluorothane anesthesia. After surgery, drinking water was replaced with 434 
0.9% NaCl, and animals were allowed to recover for 7 days. An osmotic mini-pump (Alzet 435 
Model β001; 1 μl/hr) delivering β50 μg/day of corticosterone and β50 μg/day cortisol or vehicle 436 
(DMSO: propylene glycol; 50:50 v/v) was inserted subcutaneously under anesthesia and left in 437 
place for 7 days. Abcc1+/+ and Abcc1-/- mice received no further treatment. C57Bl/6 mice were 438 
given daily s.c. injections of probenecid (150 mg/kg) or vehicle (saline). This dose was 439 
previously reported to inhibit transporter activity in vivo (42). 7 days after osmotic pump 440 
implantation, animals were culled by decapitation. Plasma was extracted from trunk blood and 441 
stored at -20 °C. Tissue was extracted and stored at -80 °C.  442 
 443 
Plasma and tissue steroid extraction and LC-MS/MS quantification 444 
Steroids were extracted from plasma by liquid-liquid extraction (chloroform, 10:1). Briefly, 445 
plasma (100 l) was enriched with internal standard (D4-cortisol and epi-corticosterone, 25 ng 446 
each). 1 ml chloroform was added and vortexed. Supernatant was reduced to dryness under 447 
oxygen-free nitrogen (OFN) at 60°C and reconstituted in mobile phase [70 l water/acetonitrile 448 
(70:30, v/v)]. Steroids were extracted from brain and adipose as previously described (20), with 449 
the substitution of D4-cortisol and D8-corticosterone as internal standards. Steroids were 450 
extracted from brain by homogenizing whole brain in methanol:acetic acid (100:1 v/v; 10 ml) 451 
and centrifuging (5000x g, 10 min, 4°C). The supernatant was reduced to dryness under OFN at 452 
60°C, reconstituted in methanol:dichloromethane:water (7:2:1, v/v; 3 ml), and enriched with 453 
internal standard (D4-cortisol and D8-corticosterone, 25 ng each). Samples were passed through 454 
a diethylaminohydroxypropyl Sephadex LH-20 anion exchange column (GE Healthcare). 455 
Columns were washed with methanol:dichloromethane:water (7:2:1, v/v; 2 ml) and 456 
methanol:dichloromethane:water (2:2:1, v/v; 1 ml). All flow-through/wash was collected and 457 
reduced to dryness under OFN at 60°C. Samples were reconstituted in methanol:acetic acid 458 
(100:1 v/v; 2 ml), and water (2 ml) was added. Samples were passed through pre-conditioned C-459 
18 Bond-Elut columns (Agilent Technologies). Columns were washed with water (2 ml), 460 
methanol:water (50:50 v/v; 3 ml), and hexane:ethyl acetate (5:1 v/v; 2 ml). Samples were eluted 461 
in ethyl acetate (2 ml), dried under OFN at 60°C and reconstituted in mobile phase [60 l 462 
water/acetonitrile (70:30, v/v)]. 463 
Quantitative analysis of steroids was carried out by liquid chromatography tandem mass 464 
spectrometry (LC-MS/MS). Chromatographic separation was achieved using a Waters Acquity 465 
UPLC system, with detection on an ABSciex QTRAP 5500 mass spectrometer operated with 466 
Analyst software version 1.6.1. The mass spectrometer was operated using the Turbospray Ion 467 
source, with nitrogen as the source, curtain and collision gas (40 and 60 psi, medium), source 468 
temperature of 550oC, spray voltage of 4.5 kV, and an entrance potential of 10 V. Compound-469 
specific tuning was performed using methanolic solutions of steroids and isotopically labeled 470 
internal standards. The protonated molecular ions were subjected to collision-induced 471 
dissociation, and the most abundant precursor-product transitions were selected; m/z 347.2  472 
91.1, 121.1 at 69 V, m/z 355.1  337.0 at 19 V, m/z 363.2  121.0, 77.0 at 29 and 101 V, and 473 
m/z 367.0  121.1 at 29 and 101 V collision energy for corticosterone, D8-corticosterone, 474 
cortisol, and D4-cortisol, respectively. Analytes were eluted on a Waters Sunfire C18 column 475 
(150 x 2.1 mm; 3.5 m) at 30oC (injection volume; 30 L) protected by a Kinetex KrudKatcher 476 
at a flow rate of 0.5 mL/min, starting at 30:70 and rising linearly to 90:10 [water+0.1% formic 477 
acid (FA):acetonitrile+0.1% FA] by 6 minutes and a total run time, including re-equilibration, of 478 
9 minutes. The peak areas were integrated using Xcalibur software (Thermo Electron) and 479 
quantified against a calibration curve. Steroid concentrations are presented corrected for total 480 
tissue weight or plasma volume. 481 
Quantification of glucocorticoid-sensitive mRNA transcripts  482 
RNA analysis performed was as described above. Primer sequences and UPL probe numbers are 483 
shown in table S6. Results were corrected for abundance of the mean combination of 18S and 484 
Tbp, which was not affected by treatment. 485 
 486 
Adipose tissue steroid concentrations and ABCC1 mRNA in lean and obese humans 487 
We recruited 12 subjects who were at the Royal Infirmary of Edinburgh for elective abdominal 488 
surgery for non-malignant disease, and who did not have systemic or local active inflammation. 489 
Paired adipose tissue samples were obtained intra-operatively from the subcutaneous and 490 
visceral depots, stored on dry ice then at -80C, and extracted for steroid quantification as 491 
previously described (20) and for RNA analysis as described above.  492 
 493 
Cortisol versus corticosterone infusion in patients with Addison’s disease 494 
Participants 495 
Patients with Addison’s disease were identified from the clinic database of the Edinburgh Centre 496 
for Endocrinology and invited to attend a screening visit, where written informed consent was 497 
obtained and eligibility assessed by a medical questionnaire, physical examination, and routine 498 
blood tests. Inclusion criteria were: a diagnosis of autoimmune Addison’s disease and age >18 y. 499 
Exclusion criteria were: alcohol intake >28 units/week; abnormal screening blood results (full 500 
blood count; renal, liver, and thyroid function tests); pituitary disease; pregnant or breastfeeding; 501 
anti-inflammatory glucocorticoid therapy by any route in the preceding 3 months; cardiac, renal 502 
or liver failure; uncontrolled hypertension (systolic BP >160 mmHg or diastolic >100 mmHg); 503 
blood donation in preceding 3 months (to avoid anemia); or research study participation in 504 
preceding 6 weeks.  505 
Study protocol 506 
Participants attended for study visits on two occasions, separated by at least one week. 507 
Participants withheld hydrocortisone from 14:00h on the day before each study visit, and omitted 508 
fludrocortisone (when prescribed) the morning before the study visit and on the morning of the 509 
study visit. They attended the clinical research facility at 08:00h after an overnight fast from 510 
22:00h. At t = -15 minutes, intravenous cannulae (18G) were inserted in each antecubital fossa. 511 
At t = 0, saline infusion (0.9 %, 125 ml/h) was commenced through the cannula in the left arm, 512 
and blood samples collected from the cannula in the right arm.  At t = 60 min, infusion of 513 
deuterated glucocorticoid (D8-corticosterone or D4-cortisol) was commenced. Order of steroid 514 
infusion was allocated randomly, and study participants were blinded to the order of infusate. 515 
9,11,12,12-[2H]4-cortisol (D4-cortisol) and 2,2,4,6,6,17,21,21-[2H]8-corticosterone (D8-516 
corticosterone) were obtained from Cambridge Isotope Laboratories, dissolved in pharmaceutical 517 
grade ethanol/water (90:10, v/v) and filtered to form sterile stock solutions, stored (-40 °C) for a 518 
maximum of 8 weeks. On study days, D8-corticosterone (4.18 mg/ml) or D4-cortisol (2.5 519 
mg/ml) stock solution (5 ml) was dissolved in sodium chloride 0.9% w/v (495 ml). At t = 60 min, 520 
a priming dose (0.65 mol D8-corticosterone; 0.23 mol D4-cortisol) was administered over 4 521 
minutes, followed by steady state infusion (27.6 nmol/min D8-corticosterone; 3.7 nmol/min D4-522 
cortisol) for 86 minutes. Further priming doses were administered at t = 150 min (1.95 mol D8-523 
corticosterone; 0.65 mol D4-cortisol) followed by constant infusion (111.2 nmol/min D8-524 
corticosterone; 17.2 nmol/min D4-cortisol) until t = 240 min, and at 240 min (3.89 mol D8-525 
corticosterone; 1.55 mol D4-cortisol) followed by constant infusion (277.8 nmol/min D8-526 
corticosterone; 51.5 nmol/min D4-cortisol) until t = 330 min. 527 
At t = 330 min, a needle aspiration biopsy of subcutaneous abdominal adipose tissue was 528 
obtained as previously described (36) and stored at -80 oC.  529 
Blood samples were obtained at 10-20 min intervals in potassium EDTA tubes (2.7 ml) pre-530 
chilled on wet-ice and serum gel tubes (9 ml; both Monovette, Sarstedt). Potassium EDTA tubes 531 
were centrifuged at 4 oC within 30 minutes of sampling; serum gel samples were left at room 532 
temperature for 30-45 minutes before centrifugation. Serum and plasma was stored at -80 ºC. 533 
Laboratory analyses 534 
In plasma, ACTH was quantified by ELISA (IBL International) within 6 weeks of sampling, and 535 
non-esterified fatty acids (NEFAs)(Zen-Bio) and glycerol (Sigma-Aldrich) quantified by 536 
colorimetric assays. In serum, glucocorticoids were quantified by LC-MS/MS, insulin by ELISA 537 
(DRG Diagnostics), and glucose by colorimetric assay (Cayman Chemical).  538 
LC-MS/MS analysis was undertaken as described for animal samples above with the exception 539 
that 11-epimers of corticosterone (epi-corticosterone; m/z 347.2  91.1, 121.1 at 69 V) and 540 
cortisol (epi-cortisol; (m/z 363.2  121.0, 77.0 at 29 and 101 V) were used as internal standards 541 
instead of D8-corticosterone and D4-cortisol.  542 
To account for any differences in protein binding between cortisol and corticosterone, cortisol 543 
and corticosterone isotopologs were also measured by LC-MS/MS after equilibrium dialysis of 544 
plasma. To achieve the necessary sensitivity, samples were pooled for the final steady state 545 
period from each infusion (260-330 min), and 4 x 1 mL aliquots of plasma were dialyzed into 1.5 546 
mL phosphate buffered saline across 12-14 kD dialysis membrane (Medicell) for 16 hours at 37 547 
oC, as previously described (43), before LC-MS/MS analysis of the pooled dialysate as above.  548 
Real-time qPCR was carried out in adipose tissue as with SGBS cells above. 549 
Statistical analysis 550 
For cell and mouse-based studies, comparisons were performed using two-way ANOVA with 551 
Bonferroni post-hoc tests or unpaired Student’s t tests as outlined in each figure legend. For the 552 
Addison’s disease study, data from each steady state period (80-140 min; 160-240 min; 260-330 553 
min) were averaged, and comparisons between D4-cortisol and D8-corticosterone and the 554 
interaction with changes over time were performed by two-way ANOVA. Adipose tissue data 555 
were compared with paired Student’s t tests. P values for statistically significant differences are 556 
presented in table S7. 557 
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Figures:  724 
Fig. 1. ABCC1, but not ABCB1, is expressed in human adipose tissue. (A) Transcript microarray 725 
data for members of the ABC transporter family, ranked by intensity, in subcutaneous adipose 726 
tissue from 12 healthy men. ABCC1 but not ABCB1 is highly expressed in human adipose. 727 
Reverse transcriptase polymerase chain reaction amplification (RT-PCR) showing expression of 728 
ABCB1 and ABCC1 in (B) human tissues and fully differentiated SGBS human adipocytes, (C) 729 
murine adipose, and (D) horse adipose. MNC = mononuclear cells, Sk. Mus = skeletal muscle.  730 
 731 
Fig. 2. ABCC1 preferentially exports corticosterone from adipocytes. (A) Export of 3H-cortisol 732 
and 3H-corticosterone from SGBS adipocytes after steroid loading for the previous 24 hours (480 733 
nM unlabeled steroid + 20 nM tritiated steroid). Data are expressed as a percentage of 734 
intracellular steroid counts per minute (CPM) after 24 hour loading (n = 3, *P<0.05, **P<0.01, 735 
two-way ANOVA with Bonferroni post-hoc test). (B) Coherent anti-Stokes Raman Scattering 736 
(CARS) images of SGBS cells treated with D8-corticosterone (500 nM) with or without ABCC1 737 
inhibition (MK571, 10 µM, 24 hours). Resonance of the C-H bonds abundant in lipid is 738 
represented in red; C-D resonance from D8-corticosterone is represented in green, and is more 739 
abundant with MK571 inhibition, notably in a distribution around the intracellular lipid droplets 740 
(scale bar = 20 µm). (C) Effect of ABCC1 inhibition with either MK571 (10 µM) or probenecid 741 
(PBN, 50 µM) on 3H-cortisol and 3H-corticosterone retention in SGBS adipocytes after 24 hour 742 
incubation. (n = 3, ***P<0.001 vs Vehicle, ##P<0.01, ###P<0.001 vs cortisol, two-way 743 
ANOVA with Bonferroni post-hoc test). (D) SGBS adipocytes incubated with corticosterone or 744 
cortisol (500 nM, 2 hours) in the presence or absence of probenecid (PBN, 50 µM). Transcripts 745 
measured are period circadian clock (PER1), adiponectin (ADIPOQ), adipose triglyceride lipase 746 
(ATGL), and hormone sensitive lipase (HSL). (n = 3, *P<0.05 vs Control, #P<0.05 vs – PBN, 747 
two-way ANOVA with Bonferroni post-hoc test. (E) SGBS pre-adipocytes show greater 748 
triglyceride accumulation after incubation with cortisol than corticosterone (100 nM), quantified 749 
by Oil Red O staining (n = 3, ***P<0.001 vs corticosterone, two-way ANOVA with Bonferroni 750 
post-hoc test). All data are mean ± SEM, exact P values are given in table S7. 751 
 752 
Fig. 3. Abcc1-/- deletion or pharmacological inhibition in mice results in preferential 753 
accumulation of corticosterone in adipose tissue.  (A - C) Adrenalectomized male wild type 754 
(Abcc1+/+) or ABCC1 knockout (Abcc1 -/-) FVB mice were infused with corticosterone and 755 
cortisol for 7 days. (D - E) Adrenalectomized male C57Bl/6 mice were infused with 756 
corticosterone and cortisol, together with either probenecid or vehicle (saline), for 7 days. Plasma 757 
(A,D), brain (B,E), and subcutaneous adipose (C,F) corticosterone (C’one) and cortisol were 758 
quantified by LC/MS-MS and are presented as concentrations and as corticosterone:cortisol 759 
ratios (Ratio). All data are mean ± SEM, n = 6-8 per group, (A - C) *P<0.05 vs Abcc1+/+, (D - E) 760 
*P <0.05 vs vehicle, Student’s t test, exact P values are given in table S7.  761 
 762 
Fig. 4.  Pharmacological inhibition of ABCC1 potentiates adipose GC-responsive transcript 763 
expression. (A) Plasma corticosterone (C’one) and cortisol concentrations, and their ratio, were 764 
not altered between mice receiving 7 days treatment with corticosteroid (corticosterone and 765 
cortisol 250 µg/day) in the presence or absence of probenecid (150 mg/kg/day). 766 
Adrenalectomized mice not receiving corticosteroid infusion had corticosterone or cortisol 767 
concentrations below the detectable limit (0.5 ng/ml). (B) Change in body weight of 768 
adrenalectomized mice after 7 days of treatment with corticosteroid (steroid) in the presence or 769 
absence of probenecid (PBN), or control (no corticosteroid). (C) Subcutaneous adipose transcript 770 
expression of the glucocorticoid-responsive genes period circadian clock 1 (Per1), adipose 771 
triglyceride lipase (Atgl), hormone sensitive lipase (Hsl), fatty acid synthase (Fas), 772 
diacylglycerol O-Acyltransferase 1 (Dgat1), and lipoprotein lipase (Lpl). All data are mean ± 773 
SEM (n = 7-11 per group, *P<0.05 vs control, #P<0.05 vs steroid + vehicle, two-way ANOVA 774 
with Bonferroni post-hoc test), exact P values are given in table S7. 775 
 776 
Fig. 5.  Corticosterone concentrations are low in human adipose tissue. Adipose biopsies were 777 
obtained during elective abdominal surgery from 6 lean and 6 obese patients. (A) ABCC1 mRNA 778 
concentrations were upregulated in obese subcutaneous (SC) and visceral (Visc) adipose tissue. 779 
(n = 6, *P <0.05, **P<0.01 vs lean, unpaired Student’s t tests). (B) Adipose tissue cortisol 780 
concentrations were readily detectable, but corticosterone concentrations were low or below the 781 
limit of detection (LOD) in SC and visceral adipose [samples below limit of detection are 782 
assigned a value of 0.86 pmoles/g (LOD)]. Neither cortisol nor corticosterone differed between 783 
lean and obese participants. All data are mean ± SEM, exact P values are given in table S7.            784 
 785 
Fig. 6. Human adipose tissue is more sensitive to cortisol than corticosterone. A randomized 786 
single blind crossover study with ramped infusion of deuterated cortisol (D4-Cortisol) or 787 
deuterated corticosterone (D8-Corticosterone) was conducted in 9 patients with Addison’s 788 
disease. Plasma concentrations of total cortisol and corticosterone (A) or ACTH (B) were not 789 
significantly different throughout the study. (C) Suppression of ACTH was similar during high-790 
dose infusion of cortisol or corticosterone. (D) Cortisol induced a greater rise in PER1 and LPL 791 
mRNA concentrations in subcutaneous adipose tissue (*P<0.05 vs corticosterone, paired 792 
Student’s t-tests). All data are mean ± SEM, n=9, exact P values are given in table S7. 793 
 794 
Fig. 7. Differential effects of cortisol and corticosterone in brain versus adipose are conferred by 795 
tissue-specific expression of ABC transporters. In conventional glucocorticoid replacement 796 
therapy, cortisol (hydrocortisone) action in the brain is limited by export through ABCB1, but 797 
the absence of ABCB1 in human adipose tissue allows potent effects of cortisol on peripheral 798 
metabolism. With corticosterone therapy, the lack of transport by ABCB1 in the brain allows 799 
corticosterone to exert a potent effect to suppress ACTH, but in adipose tissue, corticosterone 800 
action is limited by ABCC1, protecting against adverse effects of corticosterone on peripheral 801 
metabolism.    802 
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Table 1. Plasma biochemistry during infusion of either deuterated cortisol or corticosterone in patients with Addison’s disease. Data 803 
are mean ± SEM of within-subject averages from samples obtained during each steady state infusion period. N = 9. Comparisons were 804 
by two-way repeated measures ANOVA: only ACTH (P<0.001), non-esterified fatty acids (NEFA, (P=0.018), and insulin (P=0.042) 805 
changed with duration of steroid infusion, but there were no differences between corticosterone or cortisol infusions and no significant 806 
interactions between steroid and duration. 807 
 
Cortisol Corticosterone 
Duration of infusion (min) 0-60 80-140 160-240 260-330 0-60 80-140 160-240 260-330 
Total deuterated steroid (nM) 0 53 ± 11 190 ± 37 419 ± 74 0 34 ± 4 156 ± 15 340 ± 26 
Endogenous cortisol (nM) 18 ± 4 12 ± 2 8 ± 2 5 ± 1 22 ± 7 16 ± 5 11 ± 3 7 ± 2 
ACTH (pM) 42 ± 5 40 ± 5 37 ± 5 30 ± 5 42 ± 4 43 ± 4 38 ± 5 33 ± 5 
Glucose (mM) 4.5 ± 0.1 4.3 ± 0.1 4.4 ± 0.2 4.6 ± 0.2 4.7 ± 0.2 4.8 ± 0.2 4.7 ± 0.2 4.8 ± 0.2 
Insulin (pM) 44 ± 11 39 ± 7 38 ± 7 35 ± 6 43 ± 8 39 ± 6 37 ± 6 33 ± 5 
NEFA (µM) 333 ± 54 415 ± 59 474 ± 63 477 ± 60 338 ± 47 391 ± 50 420 ± 66 412 ± 58 
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Supplementary Materials: 1 
 2 
Fig. S1. Whole gel PCR image of ABC transporter expression in tissues and cells. (A) PCR gel 3 
of ABC transporter expression from human tissues. Lanes are denoted as follows: 1 = 4 
mononuclear cells, 2 = adipose, 3 = skeletal muscle, 4 = kidney, 5 = liver, 6 = thymus. Genes are 5 
indicated above bands. No RT ctl = negative control (without reverse transcriptase enzyme) for 6 
each sample. (B) Whole gel PCR image of ABCB1, ABCC1, and TBP in various cell lines. Lanes 7 
are denoted as follows:  1 = negative control, 2 = A549, 3 = HepG2, 4 = SGBS, 5 = HeLa, 6 = 8 
MCF-7.  9 
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 10 
 11 
 12 
Fig. S2. Correlation of ABCC1 mRNA and protein concentrations in human adipocytes.  (A and 13 
B) SGBS adipocytes and (C and D) primary human adipocytes treated with lipopolysaccharide 14 
(100 ng/ml) for the indicated times. mRNA concentrations after 2 hours of treatment (A and C) 15 
correlate with protein concentrations (B and D).  Data for mRNA are mean ± SEM, n = 3, * 16 
P<0.05 vs control (Ctl). 17 
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 18 
Fig. S3. ABCC1 inhibition in SGBS adipocytes. (A) SGBS adipocytes incubated with Calcein-19 
AM for 90 min demonstrate the extent of ABCC1 inhibition by MK571 (10 µM; n = 6, Student’s 20 
t-test: ***P<0.001 vs control). (B) Time course of 3H-corticosterone accumulation with ABCC1 21 
inhibition (MK571, 10 µM; n = 3, two-way ANOVA with Bonferroni post-hoc test: **P<0.01, 22 
***P<0.001). Dose response of 3H-corticosterone accumulation over 24 hours after ABCC1 23 
inhibition with various concentrations of (C) MK571, or (D) probenecid (PBN; n = 3,  one-way 24 
ANOVA: **P<0.01, ***P <0.001 vs 0). All data are mean ± SEM. 25 
  
 
 Submitted Manuscript:  Confidential             template updated: February 28 2012 
 
 26 
Fig. S4. Effects of ABCC1 inhibition on GR-mediated transcription. (A) A549 cells transfected 27 
with glucocorticoid-responsive MMTV-luciferase reporter and treated with corticosterone or 28 
cortisol (500 nM, 24 hours) show potentiation of response to corticosterone but not cortisol by 29 
ABCC1 inhibition (MK571, 10 µM; n = 3, two-way ANOVA with Bonferroni post-hoc test: 30 
***P<0.001 vs vehicle). (B) Glucocorticoid-responsive period circadian clock 1 (PER1) gene 31 
expression in SGBS adipocytes treated with MK571 or probenecid (PBN) for 24 hours, n = 2. 32 
(C) Glucocorticoid-responsive gene expression in SGBS adipocytes treated with corticosterone 33 
or cortisol (500 nM) in the presence of absence of probenecid (PBN, 50 µM) for 24 hours. 34 
Glucocorticoid-responsive genes are PER1, adiponectin (ADIQ), adipose triglyceride lipase 35 
(ATGL), and hormone sensitive lipase (HSL), (n = 3, Student’s t-test: *P<0.05 vs control; 36 
#P<0.05 vs PBN). All data are mean ± SEM.  37 
 38 
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 39 
Fig. S5. Optimization of CARS microscopy for detection of intracellular D8-corticosterone. (A) 40 
Raman spectra of D8-corticosterone showing peaks representing C-D bonds between 2000 and 41 
2300 cm-1. (B) Magnified Raman spectrum of D8-corticosterone between 2000 and 2400 cm-1. 42 
(C) Coherent Anti-stokes Raman Scattering (CARS) images of SGBS adipocytes treated with 43 
D8-corticosterone (10 µM, 24 hours) probed at inverse wavenumbers corresponding to the 44 
Raman spectrum and showing optimal detection at 2126 cm-1 (scale bar = 100 µm).  45 
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Table S1. Characteristics of lean and obese study participants providing adipose biopsy samples 46 
during surgery. 47 
 48 
 
Lean Obese 
Age (years) 60 ± 4 59 ± 3 
Gender (M/F) 2/4 2/4 
Body mass index (kg/m2)  23.9 ± 0.3 41.4 ± 1.9 
 49 
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Table S2. Characteristics of Addison’s study participants. 50 
 51 
 Mean ± SEM Range 
Age (years) 53 ± 5 20 - 65 
Gender (M/F) 3/6   
Body mass index (kg/m2) 24.7 ± 1.2 21.7 - 32.9 
Years since diagnosis 19 ± 3 4 - 30 
Daily hydrocortisone dose (mg) 21 ± 2 15 - 30 
Daily fludrocortisone dose (µg) 76 ± 30 0 - 300 
 52 
 53 
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Table S3. Summary of studies describing plasma corticosterone and cortisol concentrations in healthy subjects. 54 
Reference Gender (M/F) 
Age 
(years) 
Corticosterone (B) 
nM 
Cortisol (F) 
nM B/F
‡
 n Time B assay Technique 
Sweat, 1955 (23) ns ns 124.1 ± 14.4 298.0 ± 16.6 0.416 21 ns Fluorometric method 
Peterson, 1957 (24) 18/12 ns 31.7 ± 11.5 386.2 ± 33.1 0.082 30 ns Isotope dilution/fluorescence 
Ely et al, 1958 (25) ns ns 86.6 ± 5.8 300.7 ± 15.1 0.288 20 ns  Fluorometric method 
Fraser et al, 1968 (26) ns ns 19.0 (3.8-66.4) 270.3 (85.5-557) 0.067 29 ns Double isotope assay 
Huther et al, 1970 (27) M 26.8 ± 2.6 47.2 ± 6.0 403.0 ± 37.5 0.124 9
†
 1045-
1145*  Fluorometric method F 31.3 ± 4.4 49.7 ± 6.5 422.4 ± 67.8 0.118 10† 
Dluhy et al, 1972 (28) 8/2 21-34 26.3 ± 3.2 634.5 ± 55.2 0.041 10 0900 Radioimmunoassay 
Newsome, Jr. et al 
1972 (29) ns ns 11.5 ± 0.9 339.3 ± 22.1 0.034 8 ns 
Competitive protein 
binding 
Oddie et al, 1972 (30) ns ns 12.1 ± 2.6 383.4 ± 4.0 0.030 18 0900 Double isotope assay 
West et al, 1973 (31) 
M 
19-50 
11.4 ± 1.7 386 ± 36 0.030 15 
0800 Radioimmunoassay F1 20.4 ± 2.0 386 ± 36 0.053 9 
F2 16.7 ± 2.1 359 ± 21 0.047 9 
Nishida et al, 1977 (32) ns ns 23.0 ± 3.0 419.6 ± 28.7 0.055 10 0900 Radioimmunoassay 
Karssen et al, 2001 
(10) M 57 ± 1.9 16.4 ± 3.1 350.0 ± 81.5 0.047 11 ns LC-MS 
Raubenheimer et al, 
2006 (13) M 
39.2 (23-
70) 58.4 ± 9.2 830.4 ± 68.4 0.069 16 
0830-
0900 Radioimmunoassay 
 55 
Mean ± SEM or range (). ns = not specified 56 
†
 = mean of 5 samples for each subject 57 
* = approximate time inferred from clinical protocol 58 
1
 follicular phase, 2 luteal phase 59 
‡ mean [B] (nM)/mean [F] (nM) 60 
  
 
 Submitted Manuscript:  Confidential             template updated: February 28 2012 
 
Table S4. Primer sequences for PCR and corresponding expected product size. 61 
Gene ID Primer sequence 5’ to 3’ Expected 
product size (bp) 
ABCC1 
Human 
F: gcctattaccccagcatcg 69 
R: gatgcagttgcccacaca 
ABCB1 
Human 
F: aaggcatttacttcaaacttgtca 78 
R: tggattcatcagctgcatttt 
ABCG2 
Human 
F: tggcttagactcaagcacagc 67 
R: tcgtccctgcttagacatcc 
ABCC4 
Human 
F: cctggcgaattgttagctgt 68 
R: agcacggcacttaacagtga 
ABCC10 
Human 
F: agctcactgccaccaagg 76 
R: caagggaagttgttgagagga 
Abcc1 
Mouse 
F: ggaattttcggctgagtgtc 63 
R: agccaaatattgctgcacct 
Abcb1 
Mouse 
F: tgctttgtgggcaaaggta 106 
R: cacagttctgatggctgctaa 
ABCB1 
Horse 
F: tcaggtggccctggataa 157 
R: cgaactgtagacaagcgatga 
ABCC1 
Horse 
F: caaaatcatggctgccttaaa 89 
R: gaaagtgacatcgcgaaaca 
 62 
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Table S5. Human primer sequences for qPCR and corresponding probe number from Roche 63 
Universal Probe Library (UPL). 64 
Gene ID Primer sequence 5’ to 3’ Roche UPL Probe 
Number 
ABCC1 
Human 
F: gcctattaccccagcatcg 28 
R: gatgcagttgcccacaca 
ABCB1 
Human 
F: aaggcatttacttcaaacttgtca 18 
R: tggattcatcagctgcatttt 
PER1 
Human 
F: ctcttccacagctccctca 87 
R: ctttggatcggcagtggt 
LPL 
Human 
F: atgtggcccggtttatca 25 
R: ctgtatcccaagagatggacatt 
ADIPONECTIN 
 Human  
F: ggtgagaagggtgagaaagga 85 
R: tttcaccgatgtctcccttag 
ATGL 
Human 
F: ctccaccaacatccacgag 89 
R: ccctgcttgcacatctctc 
18S 
Human 
F: cttccacaggaggcctacac 46 
R: cgcaaaatatgctggaacttt 
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Table S6. Murine primer sequences for qPCR and corresponding probe number from Roche 65 
Universal Probe Library (UPL). 66 
Gene ID Primer sequence 5’ to 3’ Roche UPL Probe 
Number 
Abcc1 
Murine 
F: ggaattttcggctgagtgtc 105 
R: agccaaatattgctgcacct 
Abcb1 
Murine 
F: tgctttgtgggcaaaggta 78 
R: cacagttctgatggctgctaa 
Per1 
Murine 
F: gcttcgtggacttgacacct 71 
R: tgctttagatcggcagtggt 
Lpl 
Murine 
F: ctcgctctcagatgccctac 95 
R: ggttgtgttgcttgccatt 
Atgl 
Murine  
F: gagcttcgcgtcaccaac 89 
R: cacatctctcggaggacca 
Hsl 
Murine 
F: gcgctggaggagtgttttt 3 
R: ccgctctccagttgaacc 
Fas 
Murine 
F: ccaaatccaacatgggaca 34 
R: tgctccagggataacagca 
Dgat1 
Murine 
F: gcttctgcagtttggagacc 31 
R: tccagttctgccaaaagtaggt 
Tbp 
Murine 
F: gggagaatcatggaccagaa 97 
R: gatgggaattccaggagtca 
18S 
Murine 
F: ctcaacacgggaaacctcac 77 
R: cgctccaccaactaagaacg 
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